Lorlatinib/lorlatinib (Borina) standard usage and recommended dosage

Lorlatinib/ Lorlatinib ( Lorlatinib) is a third-generation ALK/ROS1 inhibitor, mainly used to treat ALK-positive or ROS1-positive advanced non-small cell lung cancer. Its original design was to break through the limitations of the first two generations of ALK inhibitors in terms of insufficient central nervous system penetration and drug resistance. According to the drug description, lorlatinib has good brain penetration properties and may show advantages in overcoming brain metastases.

In clinical applications, the standard recommended dose is 100 mg orally once daily. It can be taken on an empty stomach or after eating. Try to take the drug at the same time every day to maintain stable blood concentration. For patients with severe renal impairment, it is recommended to adjust the dose to 75 mg orally once daily to reduce adverse reactions caused by drug accumulation in the body. If moderate to severe liver function damage or other serious adverse reactions occur, the dose should be reduced or the medication should be suspended according to the physician's guidance.

The pharmacokinetic characteristics of lorlatinib determine that it should not be combined with strong CYP3A inducers, such as rifampicin, carbamazepine and other drugs, because it will reduce drug activity. In addition, taking it with grapefruit or products containing grapefruit ingredients may also interfere with drug metabolism. Patients should avoid stopping medication or changing doses at will during medication. Maintaining regular medication is crucial for the sustained effect of targeted therapy. It is worth noting that lorlatinib is a long-course targeted drug. It usually needs to be used for a long time based on the stability of the disease and drug resistance. Under the guidance of a doctor, the efficacy can be regularly evaluated and indicators such as blood lipids, liver function, and nervous system status can be monitored.

From a global perspective, the United States, Europe and Japan all use it as one of the main treatment options for ALK-positive lung cancer. Especially its application rate in patients with brain metastases is increasing year by year. As a new generation of ALK inhibitor, lorlatinib achieves higher target specificity through its unique molecular structure, making it attracted much attention in the field of precision medicine.

References：https://www.lorbrena.com/